AI-enabled app evaluates MRI data to help analyze dementia
Photo: Combinostics
Combinostics, a neurology technology company looking at everything from early detection and diagnosis to the ongoing management of neurological disorders, has announced the Dementia Differential Analysis report, which aims to assist clinicians in the detection and differential diagnosis of dementias. The report will be available in an upcoming software release.
Existing technologies compare against cognitively normal reference data only – the artificial intelligence-enabled application quantifies and evaluates patient MRI data against the distributions of key dementia-specific imaging biomarkers and reference data from approximately 2,000 patients with a confirmed neurodegenerative disease, including frontotemporal dementia, Alzheimer’s disease and vascular dementia, the company explained.
“The Dementia Differential Analysis report will help change the paradigm of diagnosing dementias,” contended Richard Hausmann, CEO of Combinostics. Using the company’s AI technology, it enables differential diagnostic support, furthering the company’s commitment to provide clinicians with tools for reliable, evidence-based diagnostic decisions, he added.
Based on MRI data only and using the company’s cDSI application, the Dementia Differential Analysis report helps enable radiologists and neurologists to interpret imaging data.
The report provides a clear, concise visual summary featuring the probabilities that the patient’s characteristics match those of specific diagnostic groups and comparisons against the reference imaging biomarker data: cortical atrophy score, hippocampal atrophy score (left and right), brain tissue white matter hyperintensities, and anterior versus posterior score, the company explained.
Neurologists also can integrate additional clinical data, such as demographic information, cognitive testing, cerebrospinal fluid biomarkers and more, through the cDSI, for deeper, data-driven diagnoses and decisions around additional testing, prognosis and treatment eligibility, the company added.
Twitter: @SiwickiHealthIT
Email the writer: [email protected]
Healthcare IT News is a HIMSS Media publication.
Source: Read Full Article
